- Home
- GHRS vs CGEM Comparison
GHRS vs CGEM Comparison
Compare GHRS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- CGEM
- Stock Information
- Founded
- GHRS 2018
- CGEM 2016
- Country
- GHRS Ireland
- CGEM United States
- Employees
- GHRS N/A
- CGEM N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- GHRS Health Care
- CGEM Health Care
- Exchange
- GHRS Nasdaq
- CGEM Nasdaq
- Market Cap
- GHRS 868.7M
- CGEM 730.2M
- IPO Year
- GHRS 2021
- CGEM 2021
- Fundamental
- Price
- GHRS $12.51
- CGEM $9.03
- Analyst Decision
- GHRS Strong Buy
- CGEM Strong Buy
- Analyst Count
- GHRS 3
- CGEM 7
- Target Price
- GHRS $35.67
- CGEM $32.50
- AVG Volume (30 Days)
- GHRS 1.1M
- CGEM 432.6K
- Earning Date
- GHRS 03-07-2025
- CGEM 03-13-2025
- Dividend Yield
- GHRS N/A
- CGEM N/A
- EPS Growth
- GHRS N/A
- CGEM N/A
- EPS
- GHRS N/A
- CGEM N/A
- Revenue
- GHRS N/A
- CGEM N/A
- Revenue This Year
- GHRS N/A
- CGEM N/A
- Revenue Next Year
- GHRS N/A
- CGEM N/A
- P/E Ratio
- GHRS N/A
- CGEM N/A
- Revenue Growth
- GHRS N/A
- CGEM N/A
- 52 Week Low
- GHRS $6.00
- CGEM $8.92
- 52 Week High
- GHRS $20.50
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- GHRS 51.44
- CGEM 30.40
- Support Level
- GHRS $13.50
- CGEM $9.06
- Resistance Level
- GHRS $14.91
- CGEM $9.51
- Average True Range (ATR)
- GHRS 1.58
- CGEM 0.50
- MACD
- GHRS -0.22
- CGEM -0.05
- Stochastic Oscillator
- GHRS 5.56
- CGEM 6.18
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.